About
Pangea Bio is a clinical-stage biotechnology company developing novel neuroplastic therapeutics targeting the TrkB receptor pathway to treat central nervous system disorders like dementia, schizophrenia, glaucoma, and major depressive disorder.
Explore Pangea Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.